Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Syndax Pharmaceuticals |
---|---|
Information provided by: | Syndax Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00602030 |
The purpose of this study is to evaluate the safety and efficacy of SNDX-275 in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer.
Condition | Intervention | Phase |
---|---|---|
Non-Small-Cell Lung Carcinoma Carcinoma, Non-Small Cell Lung |
Drug: SNDX-275 Drug: erlotinib |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With Non-Small Cell Lung Carcinoma After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease |
Estimated Enrollment: | 107 |
Study Start Date: | December 2007 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Lead in Open Label Phase 1 dose-finding study to identify a safe dose of SNDX-275 in combination with erlotinib for further evaluation
|
Drug: SNDX-275
Dose cohort 1: SNDX-275 5mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles) Dose cohort 2: SNDX-275 10mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)
erlotinib 150mg PO QD
|
2: Experimental
erlotinib (Tarceva) and SNDX-275
|
Drug: SNDX-275
SNDX-275 5mg or 10mg (determined by Lead in study findings) on days 1 and 15 of a 28-day cycle until progression or unacceptable toxicity develops; maximum of 6 cycles
Drug: erlotinib
erlotinib 150mg PO QD
|
3: Placebo Comparator
erlotinib (Tarceva) and matched Placebo patients in this arm who progress will be offered the opportunity to receive SNDX-275 with erlotinib for up to 6 28-day treatment cycles |
Drug: erlotinib
erlotinib 150mg PO QD
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contact: Jeannette Hasapidis | 781-419-1404 | jhasapidis@syndax.com |
Principal Investigator: | Samir Witta, MD | Rocky Mountain Cancer Centers |
Principal Investigator: | Kartik Konduri, MD | Texas Oncology - Sammons Cancer Center |
Principal Investigator: | Robert Raju, MD | Dayton Oncology |
Responsible Party: | Syndax Pharmaceuticals, Inc. ( Jeannette Hasapidis, Associate Director of Clinical Trials Management ) |
Study ID Numbers: | SNDX-275-0401 |
Study First Received: | January 25, 2008 |
Last Updated: | September 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00602030 |
Health Authority: | United States: Food and Drug Administration |
lung cancer NSCLC lung neoplasms respiratory |
Erlotinib Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Lung Neoplasms |
Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type |
Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |